. Thank you for sharing the transcripts! It seems like the company had a strong quarter, with new product launches driving significant revenue growth. Key highlights include the strong performance of Trulicity and Cyramza, as well as the rapid uptake of Jardiance and Talts. The company also provided updates on its NME pipeline, with several assets entering Phase 1. In terms of financials, the company reported a 22% growth in non-GAAP EPS for the quarter, and a 6% revenue growth with FX. The company's 2017 financial guidance remains largely unchanged, with a focus on improving margins through sales growth and productivity. Additionally, the company saw a $130 million gross net benefit in the fourth quarter, with a portion attributable to Humalog. Overall, the company is optimistic about its growth prospects and is focused on executing its strategy to drive value for shareholders and stakeholders.